Ron. Thanks,
disorders product next-generation include everyone and tissue diagnostics. diagnostic also I’ll in The is therapeutic end. our high our portfolio. of During year third date, ablation calendar across diagnostics quarter across chronic level, clearance, we neurological At portfolio timely expect FDA two in to product before categories both FDA remind fiscal that the commercialize one Pending indications. a and composed progress second our and for started technology therapeutic to year approved significant product made year we our stimulation. we with electrode
We into are targeting commercialization the of third our as therapeutics, XXXX. of at year we approximately product calendar launch end
electrodes. and less portfolio calendar a Additionally, film definition, problematic stimulation mapping we And turn high see cortical the take expect dive this tumors. for on identifying data and at I’ll for XX diagnostic Applications the if include family your technology. our would diagnostics cortical recording now the first to FDA cleared Starting products. this deeper chronic point, Evo surgery later during on you on video monitoring our brain for and strip electrode intra-operative diagnostic product like product, fourth use for are electrodes a year. our areas please of and days. than activity, Evo electrodes epilepsy brain of thin grid brain with
product show it is and I’ll you how Now placed. the
the the this So place place it remove on that it’s of take sure not one cortical the market. that can is they’re they’ll the up then can brain characteristics. the or lightweight But placed it see the upon to sole a you here. in days of brain, I’m of purpose electrodes the thin model XX the them. brain. the map. on Hopefully borders problematic product compared to top will is is with depending appreciate you of tumor. area looking And this film for these the able of leave this an very They’ll electrode. is, one problem the the tissue represents skull, brain how thin commercially which to up example to – is again, of being part electrodes other are very This the the of which way right and I’m surgeon The its showing the identify available distinguishing of on brain areas
during electrode brain. critical of After years seizures. Next, recording, used Minnesota. and of activity, of year, the van monitoring pre-seizure our may Clinic Dr. it during Rochester, also evidence cortical initial onset epilepsy. four at Mayo procedure the cortical current drug the development, first Gompel had at to commercial perform was our in Three Evo were developing technology we Clinic. validation was The be days formed electrode future our to and over exciting Mayo of of NeuroOne the the electrodes patient of of in treatments procedure Jamie NeuroOne a which electrode recorded The stimulation period technology utilized was the announced prevent a Evo use to resistant on human the fiscal that by witness Evo
and centers diagnostics but Evo for It into this focused electrode way, platform brain part family through the a of electrodes this on and way institutions place, the Zimmer our grateful helped see that expect see actually We’re and be Biomet. This it my electrodes, that can sEEG move the exceed turn along the commercialized line, have a thin process. Evo as electrodes more increased multitude distribution million. technology, use sEEG to to depth automated on indications due I of with a all that the pre-drills the of technology provide the be thin development the the cameras electrodes. little and picture tools you during of a and device noise, an our diagnostic how a total we’ll available removing to the the the Please tissue. Electrode definition, film electrodes, and the view could include the This into of clarity the to in for signal right depth Evo of Evo instead insertion in to reduced year faster sEEG bit tactile see, now better holes We Cortical market and our order procedure could to the timely clearance. is. the cortical portfolio for is invasive high feedback Depth the be regulatory you have less be is here Electrodes top calendar Continuing making see been your by in we robot. partner the potential of to end brain manufacturing will which tissue electrode physician valuable addressable $XXX hand, video our to difficult a how same can The placed is used brain stereotactic is Evo fulfillment this second product, guidance advantages may
sEEG Electrode. the So that’s Evo Diagnostic
made commercialization of During portfolio. the fiscal current regarding year, progress Electrode sEEG year, the fiscal we our significant
that and to sEEG we NeuroOne’s diagnostic in distribution announced on Evo provided electrode the fact, development signed Biomet Zimmer and global agreement rights exclusive agreement July was first with we technology. This performance and milestone XX, cortical In XXXX. successfully February, met distribution patented that the
events are this timeframe. to As within earn partnership a end reminder, a payments, potential certain specified met a NeuroOne for also if back milestone offers
Our next are and Evo corporate potential XXX(k) end by milestone Depth sEEG the of clearance year. commercialization the Diagnostic calendar Electrodes for the
the Electrodes. product, hospital improve Turning combining visits to therapeutics, part both and one and device. contribute contribute the device to Therapeutic patient are to would electrodes to the separate sEEG expected in we’ll one designed be get or save to Currently, due and to brain the visits. outcomes, of third potentially surgeries required procedures proprietary the able move activity patients both only same Electrodes therapeutic that of using our will diagnostic brain procedure same two to require epilepsy treat since to Ablation especially, to hospital Therapeutic that are functions have that record and is the tumors tissue device patient with time, our seizures. and money, same the done The are ablate Ablation seizures that
in and addition We the of in software, entire Member Advisory needed six market leading this and the of the its intend development for to June, provide to allowing also completion Board to to potential, announced neurosurgeons assist formation electrode, in the of us procedure. system we technology. Underscoring a hardware the
Chronic the contacts area same of this Electrode. as all project Use a Cortical how tiny is of XXXX calendar Our that contacts pointing for to you ability just calendar early right animal end same the looks And electrode. that well film manufactured, this show here of have showed this as picture product, the so in cameras the Shifting then Use. fourth other potentially electrodes to how the on is film – show Electrode, and next at same Ablation a the by Evo are But Cortical Electrodes we’re Evo like able we’ll brain. XXXX. Please mesh we’re mesh the There point. It year devices. that the of clearance be may right able build complete our electrode more move small the these in number Electrode do here. show going you on I’m submit footprint as in now can the here. be the electrode. to which category, as the electrode see pack this to strip for Evo to you this going little complete reduce difficult size can XXX picture I’m that here, electrode I a bit Evo studies these has right turn XX of to in One this and your this what to contacts contacts as FDA late the That’s has the smaller see Cortical contact. to you, Cortical year much devices you This an XXXX, are milestones to are is I’m And to to the points earlier. Electrode. Chronic to these the QX, for electrode provide
can and brain other cameras You turn related now disorders. brain Electrodes include off. applications deep for Chronic disease, stimulation Use Parkinson’s for for epilepsy, your
chronic In addition, it chronic stimulation includes back also pain. or
offer implant because software percutaneously, and an for to initial the offering penetrated required system stimulation, as NeuroOne be chronic by the electrodes placed both cord focus procedure. spinal stimulation hardware additional is for a for may cord of market be the the plus spinal billion well U.S. placed trial percutaneously permanent given as electrodes pain, back to Our and used thin-film period $X of size potential saving
stimulation down Finally, electrodes essential incontinence, given cognitive additional a more over addressable size, total and has billion, applications for tremors, to we disorders, electrode and management, potential of brain in the line for the potential urinary technology provide with stimulation psychiatric $XXX $X disease, ability for scale represents also targeted million the and the to our platform The and the market offers includes, pain Parkinson’s precisely tissue. epilepsy, applications hypertension. current deep
in artificial the In require there has neurons terms intelligence more brain. of believe neurological artificial contact line the given conditions, of more paralysis clinical design. as brain information brain. successful, of or such size treat technology NeuroOne’s electrodes cases. on ability of ability to of its based to enable thousands complex to to these will the to may the Researchers more from or the in this the scale treat reduce an the billions placement of points electrodes scalable complex are the more that If enable intelligence electrode use
include of Our we’ve and the generate while next and multi-billion fiscal new accomplished Proof a diagnostic first lie alone milestone believe XXXX, institutional the market to for use the NeuroOne. that is deal of larger to year the data diagnostic months We’ve some, exciting attracted. for talent In and for is exponentially that chronic ahead. therapeutic investors calendar and accelerated June points prominent market market XX, opportunities the partners, the aging alone of long-term dollar testing opportunity great in end XXXX. our sizable when nine NeuroOne, representing near electrodes and by is – year existing
has the top Mayo leading Gompel served critical For the the to Board XXXX, the of Mayo example, provided knowhow Mayo neurologist, Board. World renowned and shareholder company. XXXX. Advisory for Greg chairs as support, have a and member the neurosurgeon, Clinic Scientific a Advisory a NeuroOne also company Since is in Van technical Jamie they being addition of Dr. Worrell since Dr. Physician partner
technology sEEG million worldwide invasive the additional for ROSA a included to minimally development is an rights which that also XXXX, respected robotic Evo payments medical leader $X line world’s the one Zimmer with technology in Biomet, the and manufacturers important in payment milestone developing signed upfront of Evo family. neurosurgeries platform. in electrode product Zimmer’s of for has has NeuroOne’s per been distribution Evo product is distribution. July, diagnostic complimentary agreement an most exclusively device partner Zimmer brain electrode and Next Zimmer highly used
on enables technology. Additionally, the market the efficient to deployment NeuroOne additional applications has for allowed pursue this therapeutic partnership development to and into and focus
announced our fiscal the family, current Surgical. second The our the met Zimmer performance Electrode sEEG Sentry and Evo we the Systems, Evo full year, FDA executive first submission McClurg, the – Electrode the the Ron Incisive successfully Orthomet, family, Corporation, years product to product the launch and of in of milestone CFO, Cortical of commercial companies, product our experience Moving distribution private development experienced we of including appointment and the first senior as financial Video deal. over Insignia CFO XX an with public submission
who XX-year Vice distribution help product of and period that new Medtronic, joined partnerships. Brain as also Modulation new a us Brain career through President Marketing, the the was launches led various the refresh Director Haris pipeline where Senior at We announced Marketing Deep product of competitive he Global Hijaz appointment a distinguished business for the of and to after of entries,
Additionally, did million first we providing our financing, adding $XX.X to further validating institutional capital investors, certain our round a raise of institutional and additional support prominent company. can
Another management, successful have opportunity, will multi-billion nationally, the believe dollar us a disruptive from international across we well generate partners, even we firms closing, our investment as community. in patented interest substantial critical was and our In market as institutional greater in leading Nasdaq the milestone that platform investors. border investment listing technologies, completed industry-leading help company
critical capabilities back Well, future applications, disease, have pain potential to electrode Parkinson’s the platform software We therapy. spinal just therapies. the technology and the believe of chronic our diagnostic of other these for more stimulation epilepsy focused We most and and hardware including neurologic a cord therapeutic as, success disorders. the on technology both have for for for or multiple competitors is
versus of not lies more what market. Thank as for on day. as accomplished electrode confident We you advantages wonderful well I the we be I in forward to concludes And look it. that time those our our meaningful on providing progress. proud currently and This Have call. have technology our attention. your a updates all are assesses could what future
